Kingdon Capital Management L.L.C. Sells 50,479 Shares of Alcobra Ltd. (ADHD)
Kingdon Capital Management L.L.C. lessened its stake in shares of Alcobra Ltd. (NASDAQ:ADHD) by 14.4% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 300,945 shares of the biotechnology company’s stock after selling 50,479 shares during the quarter. Kingdon Capital Management L.L.C. owned 1.09% of Alcobra worth $337,000 at the end of the most recent reporting period.
Several other institutional investors also recently bought and sold shares of ADHD. Royce & Associates LP lifted its position in shares of Alcobra by 15.5% during the 1st quarter. Royce & Associates LP now owns 745,055 shares of the biotechnology company’s stock worth $849,000 after buying an additional 100,000 shares during the period. Citadel Advisors LLC lifted its position in shares of Alcobra by 7,251.0% during the 1st quarter. Citadel Advisors LLC now owns 100,114 shares of the biotechnology company’s stock worth $114,000 after buying an additional 101,514 shares during the period. Finally, Worth Venture Partners LLC lifted its position in shares of Alcobra by 35.6% during the 2nd quarter. Worth Venture Partners LLC now owns 271,982 shares of the biotechnology company’s stock worth $305,000 after buying an additional 71,465 shares during the period. Institutional investors and hedge funds own 29.68% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This news story was reported by Watch List News and is owned by of Watch List News. If you are viewing this news story on another domain, it was copied illegally and republished in violation of international copyright and trademark legislation. The legal version of this news story can be read at https://www.watchlistnews.com/kingdon-capital-management-l-l-c-sells-50479-shares-of-alcobra-ltd-adhd/1615609.html.
Several equities analysts recently commented on the company. Zacks Investment Research upgraded Alcobra from a “hold” rating to a “buy” rating and set a $1.25 target price for the company in a research report on Wednesday. Roth Capital downgraded Alcobra from a “buy” rating to a “neutral” rating and cut their target price for the stock from $4.00 to $1.00 in a research report on Friday, September 29th. Finally, Jefferies Group LLC restated a “hold” rating and set a $1.25 target price on shares of Alcobra in a research report on Monday, June 12th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and one has issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $1.55.
Alcobra Ltd. (NASDAQ ADHD) traded up 3.96% during midday trading on Friday, hitting $1.05. The stock had a trading volume of 636,013 shares. The company’s market capitalization is $28.94 million. The company’s 50-day moving average price is $1.05 and its 200 day moving average price is $1.11. Alcobra Ltd. has a 52 week low of $0.83 and a 52 week high of $2.68.
Alcobra (NASDAQ:ADHD) last announced its quarterly earnings data on Friday, August 11th. The biotechnology company reported ($0.13) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.15) by $0.02. On average, analysts expect that Alcobra Ltd. will post ($0.50) EPS for the current year.
Alcobra Ltd is a development-stage biopharmaceutical company. The Company is focused on development and commercialization of its lead product candidates, including MDX and ADAIR. MDX is a oral drug, for the treatment of ADHD and other cognitive disorders, including Fragile X. MDX is a combined rapid onset ER formulation of the chemical pyridoxine pyroglutamate, which is more commonly known as metadoxine.
Want to see what other hedge funds are holding ADHD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alcobra Ltd. (NASDAQ:ADHD).
Receive News & Ratings for Alcobra Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alcobra Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.